CD Protein Inhibitors 

  Products    Products    Diseases    News 


«12...6263646566676869707172...39323933»
  • ||||||||||  Opdivo (nivolumab) / BMS
    Trial completion date, Trial primary completion date, Checkpoint inhibition, Metastases:  Irreversible Electroporation (NanoKnife  (clinicaltrials.gov) -  Aug 9, 2024   
    P1/2,  N=12, Not yet recruiting, 
    Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
  • ||||||||||  HPN-217 / Merck (MSD)
    Trial completion date:  Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (HPN217) (clinicaltrials.gov) -  Aug 9, 2024   
    P1,  N=100, Active, not recruiting, 
    Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2026 --> Dec 2027 Trial completion date: May 2025 --> Nov 2025
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Journal, Metastases:  A Rare Case of Metastatic Adrenal Melanoma. (Pubmed Central) -  Aug 9, 2024   
    Immunotherapy demonstrated efficacy but also highlighted the emergence of immune-related adverse events, notably hyperglycemia. This case discusses the heterogeneous nature of metastatic melanoma and underscores the importance of a multidisciplinary approach, close monitoring, and consideration of evolving treatment strategies in its management.
  • ||||||||||  Opdivo (nivolumab) / BMS
    Journal, Metastases:  Efficacy of timing?dependent infusion of nivolumab in patients with advanced gastric cancer. (Pubmed Central) -  Aug 9, 2024   
    Furthermore, univariate analysis showed that early timing, immune-related adverse events and nonsteroidal anti-inflammatory drug administration were associated with longer OS and PFS. Cutoff Finder analysis revealed that the optimal timing of nivolumab administration for achieving better outcomes was before 12:06 p.m. Nivolumab administration in the morning, especially before 12:06 p.m., had a better clinical impact on patients with advanced GC.
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca
    Journal, Real-world evidence, Real-world:  Omission of staging PET/CT linked to reduced survival in stage III non-small cell lung cancer: insights from the LUCAS project real-world data. (Pubmed Central) -  Aug 9, 2024   
    Even in such a groundbreaking study, the phase 3 trial PACIFIC investigating the efficacy of durvalumab as consolidation therapy in patients with stage III NSCLC PET/CT was not mandatory...Omission of PET/CT can mean a significant decrement in survival for the patients in stage III NSCLC, likely due to poor staging and suboptimal treatment. Routine use of PET/CT is strictly recommended for the optimal management of stage III NSCLC patients even outside the high-income countries.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Herceptin (trastuzumab) / Roche
    Review, Journal, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases:  Pembrolizumab in combination with trastuzumab for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer. (Pubmed Central) -  Aug 9, 2024   
    Furthermore, ongoing research into the gastric cancer microenvironment and the role of the microbiome suggests novel targets for future therapeutic interventions. The integration of targeted and immunotherapeutic agents with traditional chemotherapy represents a pivotal shift in gastric cancer treatment, moving towards more personalized and effective regimens.
  • ||||||||||  Rituxan (rituximab) / Roche
    Journal:  Primary Sj (Pubmed Central) -  Aug 9, 2024   
    The integration of targeted and immunotherapeutic agents with traditional chemotherapy represents a pivotal shift in gastric cancer treatment, moving towards more personalized and effective regimens. She was treated with Pilocarpine 5
  • ||||||||||  Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Comprehensive treatment of gallbladder cancer: a case report. (Pubmed Central) -  Aug 9, 2024   
    The authors changed the treatment regimen to gemcitabine and oxaliplatin (GEMOX) combined with targeted therapy (lenvatinib) and immunotherapy (toripalimab), and achieved significant therapeutic effect...The adjustment of strategy can not only improve the therapeutic effect but also promote the success of surgical intervention. This case provides a valuable lesson in the holistic management of gallbladder cancer patients and prompts further reflection on the nuances of individualized therapeutic approaches in cancer treatment.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Trial completion date, Trial primary completion date, IO biomarker:  Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer (clinicaltrials.gov) -  Aug 9, 2024   
    P1,  N=16, Active, not recruiting, 
    This case provides a valuable lesson in the holistic management of gallbladder cancer patients and prompts further reflection on the nuances of individualized therapeutic approaches in cancer treatment. Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
  • ||||||||||  CHS-006 / Coherus Biosci, Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
    Trial completion date, Trial termination, Trial primary completion date, Combination therapy, Monotherapy, Metastases:  Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Aug 9, 2024   
    P1/2,  N=22, Terminated, 
    Not yet recruiting --> Recruiting Trial completion date: Jan 2026 --> Jul 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2026 --> Jul 2024; The study was terminated for strategic reasons (not for safety concerns)
  • ||||||||||  Monjuvi (tafasitamab-cxix) / Incyte
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma (clinicaltrials.gov) -  Aug 9, 2024   
    P2,  N=4, Terminated, 
    Trial completion date: Jan 2026 --> Jul 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2026 --> Jul 2024; The study was terminated for strategic reasons (not for safety concerns) N=39 --> 4 | Trial completion date: Mar 2025 --> Aug 2024 | Recruiting --> Terminated | Trial primary completion date: Mar 2025 --> Aug 2024; Slow accrual rate
  • ||||||||||  NG-641 / Akamis Bio
    Enrollment closed, Combination therapy, Monotherapy:  MOAT: A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) -  Aug 9, 2024   
    P1,  N=36, Active, not recruiting, 
    N=39 --> 4 | Trial completion date: Mar 2025 --> Aug 2024 | Recruiting --> Terminated | Trial primary completion date: Mar 2025 --> Aug 2024; Slow accrual rate Recruiting --> Active, not recruiting
  • ||||||||||  VRC01 / Acuitas Therap
    Discordant VRC01 sensitivity phenotype in participants with HIV-1 multi-lineage infections from the AMP trials () -  Aug 9, 2024 - Abstract #HIVR4P2024HIVR4P_894;    
    The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Tuesday, 8 October 2024, at 08:30 am Central Daylight Time (CDT). If an abstract is part of an official HIVR4P 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
  • ||||||||||  VRC01 / Acuitas Therap
    Structure of a neutralizing VRC01-class antibody elicited after prime-boost germline-targeting immunization regimen (Cusco Ballroom/Channel 4) -  Aug 9, 2024 - Abstract #HIVR4P2024HIVR4P_321;    
    The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Tuesday, 8 October 2024, at 08:30 am Central Daylight Time (CDT). If an abstract is part of an official HIVR4P 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
  • ||||||||||  VRC01 / Acuitas Therap
    Defining the contribution of HIV-1 subtype C CD4 binding site mutations to VRC01 resistance and viral fitness. (Cusco Ballroom/Channel 4) -  Aug 9, 2024 - Abstract #HIVR4P2024HIVR4P_193;    
    The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Tuesday, 8 October 2024, at 08:30 am Central Daylight Time (CDT). If an abstract is part of an official HIVR4P 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
  • ||||||||||  Rituxan (rituximab) / Roche
    DPPX Autoimmune Encephalitis Associated with Severe Multifocal Dystonia. (Poster Hall (Exhibit Hall A)) -  Aug 9, 2024 - Abstract #MDSCongress2024MDS_Congress_1846;    
    DPPX encephalitis presenting as new-onset focal dystonia has not been previously described. Our report expands motor phenomenology that may be associated with this autoimmune condition.
  • ||||||||||  Rituxan (rituximab) / Roche
    Progressive cerebellar ataxia in primary Sj (Poster Hall (Exhibit Hall A)) -  Aug 9, 2024 - Abstract #MDSCongress2024MDS_Congress_1503;    
    This case highlights the need for clinicians to consider autoimmune etiologies in patients presenting with progressive ataxia, especially systemic autoimmune diseases such as pSS. Early recognition and management of neurological complications in pSS are crucial to prevent irreversible disability and improve patient outcomes.
  • ||||||||||  nibrozetone (RRx-001) / EpicentRx
    Validating the clinical stage NLRP3 inflammasome inhibitor nibrozetone as a disease-modifying therapeutic for Parkinson's disease (Poster Hall (Exhibit Hall A)) -  Aug 9, 2024 - Abstract #MDSCongress2024MDS_Congress_991;    
    Early recognition and management of neurological complications in pSS are crucial to prevent irreversible disability and improve patient outcomes. Given the excellent clinical safety record of RRx-001 in human studies to date, our results suggest that RRx-001 could be an attractive neuroprotective strategy for disease modification of PD, with the potential for rapid clinical translation.
  • ||||||||||  olanzapine / Generic mfg.
    Oro-facial Dyskinesia and akathisia following Treatment by Olanzapine (Poster Hall (Exhibit Hall A)) -  Aug 9, 2024 - Abstract #MDSCongress2024MDS_Congress_662;    
    Given the excellent clinical safety record of RRx-001 in human studies to date, our results suggest that RRx-001 could be an attractive neuroprotective strategy for disease modification of PD, with the potential for rapid clinical translation. He was treated for his Neurobeh
  • ||||||||||  NG-641 / Akamis Bio
    Enrollment closed, Phase classification, Trial completion date, Trial primary completion date, Combination therapy, Metastases, Viral vector:  NEBULA: Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (clinicaltrials.gov) -  Aug 9, 2024   
    P1,  N=30, Active, not recruiting, 
    Because many patients do not report autonomic symptoms we think they should always be explored for early diagnosis and treatment. Recruiting --> Active, not recruiting | Phase classification: P1a/1b --> P1 | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: May 2024 --> Aug 2024
  • ||||||||||  Opdivo (nivolumab) / BMS, Copiktra (duvelisib) / Secura Bio, Yakult Honsha
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma (clinicaltrials.gov) -  Aug 9, 2024   
    P1/2,  N=13, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=42 --> 13 | Trial completion date: Oct 2029 --> Dec 2028 | Trial primary completion date: Apr 2028 --> Feb 2024